Top

Published in:

01-12-2013 | Current Opinion

Assessing the Cost Effectiveness of Pre-Exposure Prophylaxis for HIV Prevention in the US

Author: Fred J. Hellinger

Published in: PharmacoEconomics | Issue 12/2013

Abstract

About 50,000 people are infected with HIV in the US each year and this number has remained virtually the same for the past decade. Yet, in the last few years, evidence from several multinational randomized clinical trials has shown that the provision of antiretroviral drug to uninfected persons (i.e. pre-exposure prophylaxis) reduces the incidence of HIV by about 50 %. However, evidence from cost-effectiveness studies conducted in the US yield widely varying estimates of the cost per quality-adjusted life-year (QALY) gained, and this variation reflects the substantial uncertainty surrounding the determinants of HIV transmission (e.g. adherence rates to prophylactic medications, the average number of sexual partners, the number and types of sexual acts, the viral load of infected partners, and the proportion of contacts where condoms are used), as well as different approaches to translating a reduction in HIV cases into an estimate of the increase in the number of QALYs.

Mathers BM, Degenhardt L, Bucello C, Lemon J, Wiessing L, Hickman M. Mortality among people who inject drugs: a systematic review and meta-analysis. Bull World Health Organ. 2013;91(2):102–23.PubMedCrossRef

Schneider G, Juday T, Wentworth C 3rd, Lanes S, Hebden T, Seekins D. Impact of health care payer type on HIV stage of illness at time of initiation of antiretroviral therapy in the USA. AIDS Care. 2013;25(11):1470–6.PubMedCrossRef

Dilernia DA, Monaco DC, Cesar C, Krolewiecki AJ, Friedman SR, Cahn P, Salomon H. Estimation of HIV-testing rates to maximize early diagnosis-derived benefits at the individual and population level. PLoS One. 2013;8(1):e53193.PubMedCrossRef

Nakagawa F, Lodwick RK, Smith CJ, Smith R, Cambiano V, Lundgren JD, Delpech V, Phillips AN. Projected life expectancy of people with HIV according to timing of diagnosis. AIDS. 2012;26(3):335–43.PubMedCrossRef

Hall HI, Song R, Rhodes P, et al. Estimation of HIV incidence in the United States. JAMA. 2008;300:520–9.PubMedCrossRef

US Centers for Disease Control and Prevention. Interim guidance for clinicians considering the use of preexposure prophylaxis for the prevention of HIV infection in heterosexually active adults. MMWR Morb Mortal Wkly Rep. 2012;61(31):586–9.

Prejean J, Song R, Hernandez A, Ziebell R, Green T, et al. Estimated HIV incidence in the United States, 2006–2009. PLoS ONE. 2011;6(8):e17502.PubMedCrossRef

Sullivan PS, Carballo-Diéguez A, Coates T, Goodreau SM, McGowan I, Sanders EJ, Smith A, Goswami P, Sanchez J. Successes and challenges of HIV prevention in men who have sex with men. Lancet. 2012;380(9839):388–99.PubMedCrossRef

Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365:493–505.PubMedCrossRef

10.

Amico KR, McMahan V, Goicochea P, Vargas L, Marcus JL, Grant RM, et al. Supporting study product use and accuracy in self-report in the iPrEx study: next step counseling and neutral assessment. AIDS Behav. 2012;16(5):1243–59.CrossRef

11.

Cremin I, Alsallaq R, Dybul M, Piot P, Garnett G, Hallett TB. The new role of antiretrovirals in combination HIV prevention: a mathematical modelling analysis. AIDS. 2013;27(3):447–58.PubMedCrossRef

12.

HIV Modelling Consortium Treatment as Prevention Editorial Writing Group. HIV treatment as prevention: models, data, and questions—towards evidence-based decision-making. PLoS Med. 2012;9(7):e1001259.CrossRef

13.

Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363:2587–99.PubMedCrossRef

14.

Cohen J. Breakthrough of the year: HIV treatment as prevention. Science. 2011;34:1628–9.CrossRef

15.

Underhill K. Paying for prevention: challenges to health insurance coverage for biomedical HIV prevention in the United States. Am J Law Med. 2012;38(4):607–66.PubMed

16.

Gomez GB, Borquez A, Case KK, Wheelock A, Vassall A, Hankins C. The cost and impact of scaling up pre-exposure prophylaxis for HIV prevention: a systematic review of cost-effectiveness modelling studies. PLoS Med. 2013;10(3):e1001401.PubMedCrossRef

17.

World Health Organization. Guidance on pre-exposure oral prophylaxis (PrEP) for serodiscordant couples, men and transgender women who have sex with men at high risk of HIV: recommendations for use in the context of demonstration projects. Geneva, Switzerland; 2012.

18.

Krakower D, Mayer KH. What primary care providers need to know about preexposure prophylaxis for HIV prevention: a narrative review. Ann Intern Med. 2012;157(7):490–7.PubMedCrossRef

19.

Okwundu CI, Uthman OA, Okoromah CA. Antiretroviral pre-exposure prophylaxis (PrEP) for preventing HIV in high-risk individuals. Cochrane Database Syst Rev. 2012;(7):CD007189.

20.

Karim AQ, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010;329:1168–74.CrossRef

21.

Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367:399–410.PubMedCrossRef

22.

Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367:423–34.PubMedCrossRef

23.

Van Damme L, Corneli A, Ahmed K, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012;367:411–22.PubMedCrossRef

24.

Microbicide Trials Network. Backgrounder: VOICE—Vaginal and Oral Interventions to Control the Epidemic. National Institute of Allergy and Infectious Diseases (NIH), 18 Nov 2012. (http://www.mtnstopshiv.org/news/studies/mtn003/backgrounder).

25.

Vermund SH, Hayes RJ. Combination prevention: new hope for stopping the epidemic. Curr HIV/AIDS Rep. 2013;10(2):169–86.PubMedCrossRef

26.

Hankins CA, Dybul MR. The promise of pre-exposure prophylaxis with antiretroviral drugs to prevent HIV transmission: a review. Curr Opin HIV AIDS. 2013;8(1):50–8.PubMedCrossRef

27.

Stanley EA. Social networks and mathematical modeling. Connections. 2006;27(1):43–9.

28.

Hyman JM, Stanley EA. Using mathematical models to understand the AIDS epidemic. Math Biosci. 1988;90:415–73.CrossRef

29.

Juusola JL, Brandeau ML, Long EF, Owens DK, Bendavid E. The cost-effectiveness of symptom-based and routine screening for acute HIV infection in men who have sex with men in the USA. AIDS. 2011;25:1779–87.PubMedCrossRef

30.

Vallabhaneni S, et al. Seroadaptive behavior: association with seroconversion among HIV-MSM. In: Nineteenth Conference on Retroviruses and Opportunistic Infections (CROI), Seattle [abstract 140]; 2012 (the abstract is available on the official conference website)

31.

Baggaley RF, Fraser C. Modelling sexual transmission of HIV: testing the assumptions, validating the predictions. Curr Opin HIV AIDS. 2010;5:269–76.PubMedCrossRef

32.

Curran JW, Jaffe HW, Hardy AM, Morgan WM, Selki RM, Dondero TJ. Epidemiology of HIV infection and AIDS in the United States. Science. 1988;239:610–6.PubMedCrossRef

33.

Hethcote HW, Van Ark JW. Epidemiological models for heterogeneous populations: proportionate mixing, parameter estimation, and immunization programs. Math Biosci. 1987;84:85–118.CrossRef

34.

Wiley JA, Herschkorn S, Padian N. Heterogeneity in the probability of HIV transmission per sexual contact. Stat Med. 1989;8:93–102.PubMedCrossRef

35.

Nonacs P, Kapheim KM. Modeling disease evolution with multilevel selection: HIV as a quasispecies social genome. J Evol Med. 2012;1:1.CrossRef

36.

Zintzaras E, Kowald A. A mathematical model of HIV dynamics in the presence of a rescuing virus with replication deficiency. Theory Biosci. 2011;130(2):127.PubMedCrossRef

37.

Yuan Y, Allen LJ. Stochastic models for virus and immune system dynamics. Math Biosci. 2011;234(2):84.PubMedCrossRef

38.

Mathieu E, Loup P, Dellamonica P, Daures JP. Markov modelling of immunological and virological states in HIV-1 infected patients. Biom J. 2005;47(6):834–46.PubMedCrossRef

39.

Hendriks JC, Satten GA, Longini IM, van Druten HA, Schellekens PT, Coutinho RA, van Griensven GJ. Use of immunological markers and continuous-time Markov models to estimate progression of HIV infection in homosexual men. AIDS. 1996;10(6):649–56.PubMedCrossRef

40.

Ruff CT, Ray SC, Kwon P, Zinn R, Pendleton A, Hutton N, Ashworth R, Gange S, Quinn TC, Siliciano RF, Persaud D. Persistence of wild-type virus and lack of temporal structure in the latent reservoir for human immunodeficiency virus type 1 in pediatric patients with extensive antiretroviral exposure. J Virol. 2002;76(18):9481–92.PubMedCrossRef

41.

Finzi D, Blankson J, Siliciano JD, et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med. 1999;5:512–7.PubMedCrossRef

42.

Manner IW, Trøseid M, Oektedalen O, Baekken M, Os I. Low nadir CD4 cell count predicts sustained hypertension in HIV-infected individuals. J Clin Hypertens (Greenwich). 2013;15(2):101–6.CrossRef

43.

Kaufmann GR, Furrer H, Ledergerber B, Perrin L, Opravil M, Vernazza P, Cavassini M, Bernasconi E, Rickenbach M, Hirschel B, Battegay M, Swiss HIV Cohort Study. Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy. Clin Infect Dis. 2005;41(3):361–72.PubMedCrossRef

44.

Baraboutis IG, Papastamopoulos V, Georgiou O, Skoutelis AT. Revertant multiresistant HIV in chronically infected drug naïve patients: when baseline resistance testing is not enough. Int J STD AIDS. 2007;18(10):722–4.PubMedCrossRef

45.

US Federal Funding for HIV/AIDS. The President’s FY 2012 Budget, Kaiser Family Foundation HIV/AIDS Policy Fact Sheet; 2011.

46.

Kates J. Spending on the HIV/AIDS epidemic: trends in U.S. spending on HIV/AIDS, Menlo Park, California. The Henry J. Kaiser Family Foundation; 2002.

47.

Sanders GD, Bayoumi AM, Sundaram V, Bilir SP, Neukermans CP, Rydzak CE, Douglass LR, Lazzeroni LC, Holodniy M, Owens DK. Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy. N Engl J Med. 2005;352(6):570–85.PubMedCrossRef

48.

Paltiel AD, Weinstein MC, Kimmel AD, et al. Expanded screening for HIV in the United States: an analysis of cost-effectiveness. N Engl J Med. 2005;352:586–95.

49.

Walensky RP, Park JE, Wood R, Freedberg KA, Scott CA, Bekker LG, Losina E, Mayer KH, Seage GR 3rd, Paltiel AD. The cost-effectiveness of pre-exposure prophylaxis for HIV infection in South African women. Clin Infect Dis. 2012;54(10):4–13.

50.

Desai K, Sansom SL, Ackers ML, Stewart SR, Hall HI, et al. Modeling the impact of HIV chemoprophylaxis strategies among men who have sex with men in the United States: HIV infections prevented and cost-effectiveness. AIDS. 2008;22:1829–39.PubMedCrossRef

51.

Paltiel AD, Freedberg KA, Scott CA, Schackman BR, Losina E, et al. HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness. Clin Infect Dis. 2009;48:806–15.PubMedCrossRef

52.

Freedberg KA, Losina E, Weinstein MC, Paltiel AD, Cohen CJ, Seage GR, Craven DE, Zhang H, Kimmel AD, Goldie SJ. The cost effectiveness of combination antiretroviral therapy for HIV disease. N Engl J Med. 2001;344(11):824–31.PubMedCrossRef

53.

Juusola JL, Brandeau ML, Owens DK, Bendavid E. The cost-effectiveness of pre-exposure prophylaxis for HIV prevention in the United States in men who have sex with men. Ann Intern Med. 2012;156:541–50.PubMedCrossRef

54.

Koppenhaver RT, Sorensen SW, Farnham PG, Sansom SL. The cost-effectiveness of pre-exposure prophylaxis in men who have sex with men in the United States: an epidemic model. J Acquir Immune Defic Syndr. 2011;58:e51–2.PubMedCrossRef

55.

Farnham PG, Holtgrave DR, Sansom SL, Hall HI. Medical costs averted by HIV prevention efforts in the United States, 1991–2006. JAIDS. 2010;54(5):565–7.PubMed

56.

Braithwaite RS, Meltzer DO, King JT Jr, Leslie D, Roberts MS. What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule? Med Care. 2008;46(4):349–56.PubMedCrossRef

57.

Pierson R. WHO endorses use of HIV medicines for prevention. Chicago Tribune; 2012.

58.

Keller SB, Smith DM. The price of tenofovir-emtricitabine undermines the cost-effectiveness and advancement of pre-exposure prophylaxis. AIDS. 2011;25(18):2308–10.PubMedCrossRef

59.

Waning B, et al. Temporal trends in generic and brand prices of antiretroviral medicines procured with donor funds in developing countries. J Generic Med. 2010;7(2):159–75.CrossRef

60.

Rayment M. Prevention of HIV-1 infection with early antiretroviral therapy. J Fam Plan Reprod Health Care. 2012;38:193.CrossRef

61.

Mermin J, Fenton KA. The future of HIV prevention in the United States. JAMA. 2012;308(4):347–8.PubMedCrossRef

62.

Williams B et al. Treatment as prevention: preparing the way. J Int AIDS Soc. 2010;14(1). http://www.avert.org/hiv-treatment-as-prevention.htm#sthash.QL8HClqI.dpuf.

63.

Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, Augustovski F, Briggs AH, Mauskopf J, Loder E, ISPOR Health Economic Evaluation Publication Guidelines-CHEERS Good Reporting Practices Task Force. Consolidated Health Economic Evaluation Reporting Standards (CHEERS). Value Health. 2013;16(2):231–50.PubMedCrossRef

Title: Assessing the Cost Effectiveness of Pre-Exposure Prophylaxis for HIV Prevention in the US
Author: Fred J. Hellinger
Publication date: 01-12-2013
Publisher: Springer International Publishing
Published in: PharmacoEconomics / Issue 12/2013
Print ISSN: 1170-7690
Electronic ISSN: 1179-2027
DOI: https://doi.org/10.1007/s40273-013-0111-0

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Assessing the Cost Effectiveness of Pre-Exposure Prophylaxis for HIV Prevention in the US

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 12/2013

A Closer Look at Decision and Analyst Error by Including Nonlinearities in Discrete Choice Models: Implications on Willingness-to-Pay Estimates Derived from Discrete Choice Data in Healthcare

The Estimation of Utility Weights in Cost-Utility Analysis for Mental Disorders: A Systematic Review

Erratum to: Cost–Utility Analysis of Deferiprone for the Treatment of β-Thalassaemia Patients with Chronic Iron Overload: A UK Perspective

How to Include Informal Care in Economic Evaluations

Cost Effectiveness of Medication Adherence-Enhancing Interventions: A Systematic Review of Trial-Based Economic Evaluations

Search MEDLINE for Economic Evaluations: Tips to Translate an OVID Strategy into a PubMed One